Accepted at 3:40 a.m. Nov, 01, 2023 by Ahmed7
Author: ma7moudgamal66
Co-authors: Ahmed7
Related Note: 1504363340097 3
Rationale for change

Accodring to UW, IV fluids should be used along allopurinol or rasburicase to help prevent/manage tumor lysis syndrome
Source: UWorld - Step 2 18770

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#NBME::20 #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::12_Lymphoma #AK_Step1_v12::#FirstAid::05_Pharm::03_Toxicities_and_Adverse_Effects::08_Drug_reactions-musculoskeletal/skin/connective_tissue #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::16_Acute_Leukemia #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::05_Tumor_Lysis_Syndrome #AK_Step1_v12::#B&B::13_Immunology::05_Inflammatory_Disorders::02_Gout_Drugs::Extra #AK_Step2_v12::#B&B::09_MSK::01_General::03_Gout::Extra #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::01_Acute_Leukemias_SOAP #AK_Step2_v12::#NBME::Form14::Section_4 #AK_Step2_v12::#SketchyIM::04_Nephrology_&_Urology::05_Retired_Lessons::01_AKI_SOAP_[OLD_VERSION] #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::03_Anti-inflammatory::02_Gout_drugs #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::08_Acute_and_Chronic_Gout_Treatment #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::09_Gout_drugs::01_Chronic_gout_drugs_(preventive)::*Allopurinol_Febuxostat #AK_Step2_v12::#FirstAid::12_Pediatrics::11_Pediatric_Oncology::01_Leukemia #AK_Step1_v12::#Physeo::05_Biochem::05_Metabolism::18_Purines_&_Pyrimidines #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::34_Tumor_lysis_syndrome #AK_Step1_v12::#Pixorize::01_Biochemistry::02_Biochemical_Pathways::08_Purine_Excretion #AK_Step1_v12::#SketchyBiochem::03_Molecular_Biology::01_DNA::06_Purine_Salvage_Pathway #AK_Step1_v12::#AMBOSS::WXaPCQ #AK_Step2_v12::#SketchyIM::07_Rheumatology::02_Crystalline_Disorders::01_Gout_&_Pseudogout_SOAP #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#OME::PreClinical::Biochemistry #PANCE::EOR::IM #AK_Step2_v12::#NBME::Form12 #AK_Step1_v12::#Bootcamp::Musculoskeletal::02_Non-Rheumatologic_Disease::02_Gout #AK_Step1_v12::#AMBOSS::C-0qzi #AK_Step2_v12::#UWorld::Step::107069 #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::13_Allopurinol/Febuxostat #AK_Step2_v12::#AMBOSS::U30b3f #AK_Step2_v12::#NBME::Form16::Section_1 #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::09_Gout_drugs